Search company, investor...


Founded Year



Other Investors | Alive

About CardioGenesis

Cardiogenesis is a medical device company committed to innovating tools for the treatment of cardiovascular disease. The company, located in Orange County, California, is a provider in laser revascularization and angiogenic therapies for the treatment of severe angina.

Headquarters Location

11 Musick

Irvine, California, 92618,

United States


Missing: CardioGenesis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CardioGenesis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

CardioGenesis Patents

CardioGenesis has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Surgical instruments, Medical equipment, Amines, Prodrugs, Plastic surgery


Application Date


Grant Date



Related Topics

Surgical instruments, Medical equipment, Amines, Prodrugs, Plastic surgery



Latest CardioGenesis News

Sologrip III Laser Fiberoptic Delivery Device for Minimally Invasive Transmyocardial Revascularization FDA Cleared

Jul 17, 2013

Cardiogenesis, a CryoLife company, has received FDA clearance to market the company’s new Sologrip III laser fiberoptic delivery device. The Sologrip III is a single use device used along with the company’s Holmium:YAG laser-based transmyocardial revascularization (TMR) system to treat angina. Minimally invasive TMR procedure involves reaching the heart through an incision between the ribs and then creating 1 mm wide channels in the myocardium that induce the muscle to generate neovasculature. Typically between 20 and 40 such channels are created during the procedure. The technique increases blood and oxygen supply to the diseased part of the heart, improving performance and reducing angina associated pain. Product page: Sologrip III… Press release: CryoLife Receives FDA Premarket Approval (PMA) for New Sologrip Minimally Invasive TMR Laser Fiber-Optic Delivery System

CardioGenesis Frequently Asked Questions (FAQ)

  • When was CardioGenesis founded?

    CardioGenesis was founded in 1989.

  • Where is CardioGenesis's headquarters?

    CardioGenesis's headquarters is located at 11 Musick, Irvine.

  • What is CardioGenesis's latest funding round?

    CardioGenesis's latest funding round is Other Investors.

  • Who are the investors of CardioGenesis?

    Investors of CardioGenesis include Vanguard Ventures.

  • Who are CardioGenesis's competitors?

    Competitors of CardioGenesis include HistoSonics, Aethlon Medical, Valtech Cardio, Nevro, Pathfinder Therapeutics and 14 more.

Compare CardioGenesis to Competitors

Paragon Intellectual Properties

Nexeon MedSystems is committed to improving lives through the development of therapies for people with cardiovascular disease. With proven medical device research and development talent, a strong intellectual property portfolio and the leadership of a veteran interventional cardiologist, Nexeon has created an pipeline of products for unmet clinical needs.


Vascure is a medical device company. The company is developing an therapeutic device for percutaneous treatment of arterial disease. Vascure's system will offer a one-stop solution for restoring blood flow to narrowed or occluded blood vessels in a range of clinical conditions, including heavily calcified lesions. Vascure will provide Intervantionalists with a safe and easy to use device, shortening procedure time, allowing percutaneous treatment in cases previously requiring radical surgical procedures and generating improved clinical outcomes.

Aethlon Medical Logo
Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier - medical device that aims to treat infectious disease.

HistoSonics Logo

HistoSonics develops a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors at sub-cellular levels. The company is focused on the development of its Edison platform, combining imaging with sensing technology to deliver personalized external beam treatments with precision and control, reducing the side effects of conventional therapies. The company was founded in 2009 and is based in Minneapolis, Minnesota.


VeinRx is developing alternative approaches to the treatment of peripheral venous disease including varicose veins.


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.